新型(基因)疫苗之研究。
三個研究報告。
由日本小兒科醫生、小兒腫瘤科醫生、心臟科醫生、醫療資料研究員、多名學者完成的研究指出:新冠疫苗的多次施打與癌症死亡人數呈現正相關。Japan Cancer rate research Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan
BRCA1 活性受損與女性罹患乳癌、子宮癌和卵巢癌以及男性罹患攝護腺癌的較高風險有關。Impaired BRCA1 activity is associated with higher risk of breast, uterine, and ovarian cancer in women and prostate cancer in men,
https://www.cureus.com/articles/196275-increased-age-adjusted-cancer-mortality-after-the-third-mrna-lipid-nanoparticle-vaccine-dose-during-the-covid-19-pan#!/https://assets.cureus.com/uploads/original_article/pdf/196275/20240408-14533-1avkjxd.pdf2023年初,MIT麻省理工學院近期世界上最重要的醫學研究計畫之一:人類基因組計劃 (Human Genome Project)的研究員 Kevin McKernan 公布研究結果,表示mRNA疫苗內含有高濃度的SV40 DNA片段汙染。SV40是已知的癌症促進物。隨後加拿大、歐洲都表示發現同樣的問題。SV40會影響重要的抑制腫瘤的基因:p53。公布研究結果,表示mRNA疫苗內含有高濃度的SV40 DNA片段汙染。SV40是已知的癌症促進物。隨後加拿大、歐洲都表示發現同樣的問題。SV40會影響重要的抑制腫瘤的基因:p53。
https://osf.io/preprints/osf/b9t7mSequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose
2023年11月新的研究報告出爐:作者為Keith Peden, PhD: FDA Office of Vaccines Research and Review
Division of Viral Products
Laboratory of DNA Viruses 也就是FDA內部研究人員。
FDA自己人用迂迴的方式來表達mRNA SV40的問題。但是其實在報告討論的部分,已經提到SV40 所以他也沒有真的很迂迴啦。
簡單來說,就是看打針的人的運氣如何(因為要看plasmid DNA的數量),所以打越多次,越容易中大獎(致癌的可能性提高)。簡單來說,FDA在2023年11月以前就知道有問題。因為是MIT研究員在2023年3月就提出來的SV40的問題。
之前沒有人提出來,因為FDA把mRNA、腺病毒藥物修改規定,將他們從藥物改列為疫苗,而疫苗規範與一般藥物規範不同,因為某種神祕的原因,沒有規定要強制研究DNA毒性。(法律漏洞)。
"However, it was not known when we initiated these studies whether these two oncogenes would be oncogenic in hamsters and rats, and the initial experiment in newborn hamsters included an expression plasmid for the SV40 early region, which expresses both large T antigen and small T antigen, and had been shown to induce tumors in newborn hamsters [8]; our studies on polyomavirus tumor antigens will be reported elsewhere (manuscript in preparation). As we report here, the pMSV-T24-H-ras/MSV-c-myc plasmid was indeed oncogenic in both newborn hamsters and newborn rats."
"In conclusion, the results presented indicate that evaluating the oncogenicity of cellular DNA has limitations even in sensitive rodent systems. Further investigation and studies are planned to examine the characteristics of the test system that may increase the value of these in vivo assays in assessing the oncogenic risk that could potentially be posed by residual cellular DNA in vaccines. Nevertheless, as a consequence of these limitations, perhaps the best way to control for and eliminate the hypothetical risk of residual DNA in vaccines is to reduce the amount and size of this DNA, an approach discussed at the September 19, 2012, meeting of the Vaccines and Related Biologicals Advisory Committee."
https://www.sciencedirect.com/science/article/pii/S1045105623000635?via=ihub